drugset
Drugs / Pocenbrodib
last change Mar 2025 re-read 9 days ago

Pocenbrodib

also known as FT-7051 · FT-7051 hydrochloride · POCENBRODIB HYDROCHLORIDE

Small molecule

Developed for
prostate carcinoma
Investigated by
Duke University · Novo Nordisk A/S · Pathos AI, Inc.

Trials 2

today NCT06785636 · Ph 1/2 NCT04575766 · Ph 1
20212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04575766 Dec 2020 → Nov 2022 prostate carcinoma Novo Nordisk A/S Terminated No outcome recorded Stop: Business
Phase 1/21 trial
Phase 1/2 NCT06785636 Feb 2025 → Jun 2028 expected prostate carcinoma Pathos AI, Inc. Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2025-03-20 Pathos AI, Inc. Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor pathos.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Pocenbrodib ClinicalTrials.gov intervention name — accepted as the source's own label NCT06785636 ↗
Known as FT-7051 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04575766 ↗
Known as FT-7051 hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL5314476 ↗
Known as POCENBRODIB HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL5314476 ↗
Action Inhibit “selective oral inhibitor of CBP/p300 bromodomain interaction” NCT06785636 ↗
Modality Small molecule — CHEMBL5314476 ↗
Route Oral “Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.” NCT04575766 ↗